Provision Language
BACKGROUND:
(A) The intent of this Agreement is to enable broad access in resource-limited countries to cabotegravir for pre-exposure prophylaxis to reduce the risk of HIV-1 infection in persons (weighing at least 35kg) at risk of acquiring HIV-1.
(B) ViiV is a pharmaceutical company focused on the needs of people living with and affected by HIV.
(C) The MPPF is a non-profit organisation with a mission to improve the health of people by increasing access to quality, safe, efficacious and affordable medicines by facilitating access to intellectual property to medicines.
Schedule 2: Form of Sublicense
WHEREAS the intent of this Agreement is to enable broad access in resource-limited countries to cabotegravir for pre-exposure prophylaxis to reduce the risk of HIV-1 infection in persons (weighing at least 35kg) at risk of acquiring HIV-1.